O P E VOJO

Atty. Docket No.:

2312/2082

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application

Raghuram Kalluri

Examiner:

N/A

Serial No.:

10/032,221

Filed:

December 21, 2001

Group Art Unit:

1646

Entitled:

Anti-Angiogenic Proteins and

Fragments and Methods of Use Thereof

Conf. No.:

3472

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to U.S. Patent and Trademark Office, Box: Sequence, P.O. Box 2327, Arlington, VA 22202.

Joyce C. Hersh-

Name of Person Mailing Paper

Signature of Person Mailing Paper

U.S. Patent and Trademark Office

Box: Sequence P.O. Box 2327

Arlington, VA 22202

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- 1. Response to Notice to File Missing Parts of Non-Provisional Application;
- 2. Copy of Notice to File Missing Parts (copy of Part 1 Attorney/Applicant Copy);
- 3. Executed Declaration and Power of Attorney;
- 4. Transmittal of Substitute Sequence Listing in Response to Notice to Comply with 37 C.F.R. § § 1.821-1.825;
- 5. Statement Under 37 C.F.R. § 1.821(f) and (g);
- 6. Substitute paper copy and computer readable Sequence Listing;
- 7. Petition for three month Extension of Time;
- 8. Check in the amount of \$2,056.00 for the requisite fee; and
- 9. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 2312/2082B. A duplicate of this transmittal letter is enclosed for this purpose.

Date: June 20, 2002

Respectfully submitted

Name: Joyce C. Hersh, Ph.D. Registration No.: 42,890

Customer No.: 29933 Palmer & Dodge LLP

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

Atty. Docket No.: 2312/2082B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Raghuram Kalluri

Serial No.:

10/032,221

Filed:

December 21, 2001

Anti-Angiogenic Proteins and

Fragments and Methods of Use

Thereof

Examiner:

N/A

Group Art Unit:

1646

Conf. No.:

3472

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being eposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to U.S. Patent and Trademark Office, Box: Sequence, P.O. Box 2327, Arlington, VA 22202.

Joyce C. Hersh

Name of Person Faxing

Signature of Person Mailing Paper

U.S. Patent and Trademark Office

Box: Sequence P.O. Box 2327

Arlington, VA 22202

RESPONSE TO NOTICE TO FILE MISSING PARTS OF NON-PROVISIONAL APPLICATION

Sir:

This is filed in response to the Notice to File Missing Parts of Non-Provisional Application mailed January 30, 2002.

- 1. The Notice stated that the basic filing fee and additional claims fee is missing. A check is enclosed in the amount of \$2,056.00 which includes:
 - a) \$370.00 basic filing fee for small entity;
 - b) \$1,161.00 additional claims fee;
 - c) \$65.00 surcharge for late filing fee or declaration; and
 - d) \$460.00 extension of time.
 - 2. The Notice stated that the Declaration is missing.

An executed Declaration/Power of Attorney is enclosed.

3. The Notice stated that the Sequence Listing does not comply with the requirements of 37 C.F.R. 1.822 and or 1.823.

The Sequence Listing on paper copy and computer readable copy are enclosed.

Date:

June 20, 2002

06/28/2002 JBALINAN 00000043 10032221

05 FC:217

460.00 OP

Name: Joyce C. Hersh, Ph.D.

Registration No.: 42,890 Customer No.: 29933

Palmer & Dodge LLP

Respectfully submitted.

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100



HAMILTON, BROOK, SMITH & REYNOLDS, P.C.







021005

UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET

10/032,221

12/21/2001

Raghuram Kalluri

1440.1027-016

CONFIRMATION NO. 3472

FORMALITIES LETTER

OC000000007390996*

P.O. BOX 9133 CONCORD, MA 01742-9133

530 VIRGINIA ROAD

DOCKETE

Date Mailed: 01/30/2002

TICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

06/28/2002 JEALINAN 00000043 10032221

FILED UNDER 37 CFR 1.53(b)

370.00 OP 378.00 DP 65.00 OP

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing. Applicant must submit \$ 740 to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$2322.
 - \$1566 for 87 total claims over 20.
 - \$756 for 9 independent claims over 3.
- The oath or declaration is missing. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(I) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 3192.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

■ For Rules Interpretation, call (703) 308-4216

Response due Statutory period

Palmer & Dodge LLP

Patent Department

02 FC:202





- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY

DOCKEIL



#3

Atty. Docket No.: 2312/2082B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Kalluri, et al.

Serial No.:

10/032,221

Filed:

December 21, 2001

Entitled:

"Anti-Angiogenic Proteins and

Fragments and Methods of Use

Thereof'

Examiner:

N/A

Group Art Unit:

1646

Conf. No.:

3472

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.82

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to U.S. Patent and Trademark Office, Box: Sequence, P.O. Box 2327, Arlington, VA 22202.

Joyce C. Hersh

Name of Person Mailing

Signature of Person Mailing Paper

U.S. Patent & Trademark Office

Box: Sequence P.O. Box 2327

Arlington, VA 22202

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING IN RESPONSE TO NOTICE TO COMPLY WITH 37 C.F.R. §§1.821-1.825

Sir:

This amendment is submitted in response to the Notice to File Missing Parts of Application, and the Notice to Comply with Sequence Rules 37 C.F.R. §§1.821-1.825 attached thereto, mailed from the Patent Office on January 30, 2002, copies of which are attached.

Applicant's Attorney requests an extension of time to respond to the Notice. A Petition for the Extension and the appropriate fees are being filed concurrently.

Transmitted herewith is a copy of the substitute "Sequence Listing" (sheets 1 through 21) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the Sequence Listing in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the

Serial No.: 10/032,221 Docket No.: 2312/2082B

"Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Respectfully submitted,

Date:

June 20, 2002

Joyce C. Hersh, Ph.D.


Registration No.: 42,890

Palmer & Dodge LLP 111 Huntington Avenue

Boston, MA 02199-7613

Telephone: (617) 239-0100

Telecopier: (617) 227-4420



RAW SEQUENCE LISTING

ERROR REPORT

When totechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

	r shaar in th
Application Serial Number: 10/	032,221
Source:	OIVE
Date Processed by STIC:	1/15/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS. PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE, SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker


Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom, including:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE) 🚜
- 2. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
 - U.S. Patent and Trademark Office Box Sequence, Customer Window, Lobby, Room 1803; Crystal Plaza II w
- OS, Friend 2011 South Chris Phes, Arlington, VA 2402 Robert Frynses, United Prival Sarvics, or other delivery tervice to US. Prion and Fridein Box Sequence, Room (BOX-Mailroom, Grysen) Phys. Two, 2011 South Chris Phes, Arlingtons)

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: $\frac{10032,221}{10000000000000000000000000000000000$
ATTN: NEW RULES CASE	s: please disregard english "alpha" headers, which were inserted by pto software
lWrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's for Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH - Biotechnology Systems Branch - 08/21/2001



RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/032,221

DATE: 01/15/2002

pp 1-5

TIME: 15:30:43

Input Set : A:\14401027016.txt

Output Set: N:\CRF3\01152002\J032221.raw

4 <110> APPLICANT: Raghuram Kalluri
6 <120> TITLE OF INVENTION: ANTI-ANGIOGENIC PROTEINS AND FRAGMENTS Corrected Diskette Needec

7 AND METHODS OF USE THEREOF 10 <130> FILE REFERENCE: 1440.1027-016

- 12 <140> CURRENT APPLICATION NUMBER: US/10/032,221
- 12 <141> CURRENT FILING DATE: 2001-12-21
- 12 <150> PRIOR APPLICATION NUMBER: PCT/US01/00565
- 13 <151> PRIOR FILING DATE: 2001-01-08
- 15 <150> PRIOR APPLICATION NUMBER: US 09/543,371
- 16 <151> PRIOR FILING DATE: 2000-04-04
- 18 <150> PRIOR APPLICATION NUMBER: US 09/335,224
- 19 <151> PRIOR FILING DATE: 1999-06-17
- 21 <150> PRIOR APPLICATION NUMBER: US 60/126,175
- 22 <151> PRIOR FILING DATE: 1999-03-25
- 24 <150> PRIOR APPLICATION NUMBER: US 60/089,689
- 25 <151> PRIOR FILING DATE: 1998-06-17
- 27 <150> PRIOR APPLICATION NUMBER: US 09/479,118
- 28 <151> PRIOR FILING DATE: 2000-01-07
- 30 <150> PRIOR APPLICATION NUMBER: US 09/625,191
- 31 <151> PRIOR FILING DATE: 2000-07-21
- 33 <160> NUMBER OF SEQ ID NOS: 58
- 35 <170> SOFTWARE: FastSEQ for Windows Version 4.0

ERRORED SEQUENCES

108 <210> SEQ ID NO: 2

109 <211> LENGTH: 229

110 <212> TYPE: PRT

111 <213> ORGANISM: Homo sapiens

113 <400> SEQUENCE: 2

114 Ser Val Asp His Gly Phe Leu Val Thr Arg His Ser Gln Thr Ile Asp

5 1 5 10 15

116 Asp Pro Gln Cys Pro Ser Gly Thr Lys Ile Leu Tyr His Gly Tyr Ser 117 20 25 30

118 Leu Leu Tyr Val Gln Gly Asn Glu Arg Ala His Gly Gln Asp Leu Gly

119 . 35 . 40 4!

120 Thr Ala Gly Ser Cys Leu Arg Lys Phe Ser Thr Met Pro Phe Leu Phe

21 50 55 6

122 Cys Asn Ile Asn Asn Val Cys Asn Phe Ala Ser Arg Asn Asp Tyr Ser

123 65 70 75 80

124 Tyr Trp Leu Ser Thr Pro Glu Pro Met Pro Met Ser Met Ala Pro Ile

126 Thr Gly Glu Asn Ile Arg Pro Phe Ile Ser Arg Cys Ala Val Cys Glu

127 100 105 110

128 Ala Pro Ala Met Val Met Ala Val His Ser Gln Thr Ile Gln Ile Pro

129 115 120 125

DATE: 01/15/2002

TIME: 15:30:43

Input Set : A:\14401027016.txt Output Set: N:\CRF3\01152002\J032221.raw 130 Pro Cys Pro Ser Gly Trp Ser Ser Leu Trp Ile Gly Tyr Ser Phe Val 130 132 Met His Thr Ser Ala Gly Ala Glu Gly Ser Gly Gln Ala Leu Ala Ser 133 145 150 155 134 Pro Gly Ser Cys Leu Glu Glu Phe Arg Ser Ala Pro Phe Ile Glu Cys 170 165 136 His Gly Arg Gly Thr Cys Asn Tyr Tyr Ala Asn Ala Tyr Ser Phe Trp 185 138 Leu Ala Thr Ile Glu Arg Ser Glu Met Phe Lys Lys Pro Thr Pro Ser Linsert hard return E--> 139 Thr Leu Lys Ala Gly Glu Leu Arg 205 200 195 235 <210> SEQ ID NO: 6 236 <211> LENGTH: 227 237 <212> TYPE: PRT 238 <213> ORGANISM: Homo sapiens 240 <400> SEQUENCE: 6 241 Val Ser Ile Gly Tyr Leu Leu Val Lys His Ser Gln Thr Asp Gln Glu 243 Pro Met Cys Pro Val Gly Met Asn Lys Leu Trp Ser Gly Tyr Ser Leu 245 Leu Tyr Phe Glu Gly Gln Glu Lys Ala His Asn Gln Asp Leu Gly Leu 40 247 Ala Gly Ser Cys Leu Ala Arg Phe Ser Thr Met Pro Phe Leu Tyr Cys 249 Asn Pro Gly Asp Val Cys Tyr Tyr Ala Ser Arg Asn Asp Lys Ser Tyr 251 Trp Leu Ser Thr Thr Ala Pro Leu Pro Met Met Pro Val Ala Glu Asp 90 85 253 Glu Ile Lys Pro Tyr Ile Ser Arg Cys Ser Val Cys Glu Ala Pro Ala 105 100 255 Ile Ala Ile Ala Val His Ser Gln Asp Val Ser Ile Pro His Cys Pro 125. 120 257 Ala Gly Trp Arg Ser Leu Trp Ile Gly Tyr Ser Phe Leu Met His Thr 135 140 259 Ala Ala Gly Asp Glu Gly Gly Gln Ser Leu Val Ser Pro Gly Ser 155 150 261 Cys Leu Glu Asp Phe Arg Ala Thr Pro Phe Ile Glu Cys Asn Gly Gly 170 165 263 Arg Gly Thr Cys His Tyr Tyr Ala Asn Lys Tyr Ser Phe Trp Leu Thr 265 Thr Ile Pro Glu Gln Ser Phe Gln Gly Ser Pro Ser Ala Asp Thr Leu , insert hard return E--> 266 Lys Ala Gly Leu Ile Arg Thr His 205 430 <210> SEQ ID NO: 13 431 <211> LENGTH: 8 432 <212> TYPE: PRT 433 <213> ORGANISM: Artificial Sequence 435 <220> FEATURE: 436 <223> OTHER INFORMATION: Additional vector sequence added to protein 438 <400> SEQUENCE: 13 / insert hard return 438 <400> SEQUENCE: 13 E--> 439 Met Asp Ile Gly Ile Asn Ser Asp 1

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/032,221

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/032,221

DATE: 01/15/2002 TIME: 15:30:43

Input Set : A:\14401027016.txt

Output Set: N:\CRF3\01152002\J032221.raw

440 <210> SEQ ID NO: 14

441 <211> LENGTH: 7

442 <212> TYPE: PRT

443 <213> ORGANISM: Artificial Sequence

445 <220> FEATURE:

446 <223> OTHER INFORMATION: Additional vector sequence added to protein


set following pager for more even

E--> 449 Lys Leu Ala Ala Leu Glu I

1/15/02

	□<210>	38
	□<211>	25
	□<212>	PRT
	□<213>	Artificial Sequence
•		Ver (8250)
	□<220>	$1 \qquad \rho \cdot l_{x}$
	□<223>	T7-mutant (amino acids 74-98 of SEQ ID NO:10; Sequence Record
		methionine has been substituted for the leucine 4 lines MAX Mum fr
		Artificial Sequence Per 1.823 T7-mutant (amino acids 74-98 of SEQ ID NO:10; methionine has been substituted for the leucine residue at position 78 of the full-length C2737 response.
000		Tumstatin molecule, and isoleucine has been >/2207,
Λ ³ Σ'	12237	Tumstatin molecule, and isoleucine has been >22207 substituted for valine at position 82, and ((nsert)
	/a `	asparagine has been substituted for aspartic acid
		at position 84)
	□<400>	
	,	The types of errors shown exist throughout
		the Sequence Listing, Picase check subsequent
•		sequences for similar errors.

<210> 45 □<211> 14 Artificial Sequence □<212> PRT C<213 rtificial Sequence **□<220>** □<223> Generic peptide □<223> X at position 1 is a hydrogen or a peptidyl chain of 1 to 17 amino acids invalid - Xaa can only request a single amend oeid (see tem 5 on Evor Sunnary \square <223> X at position 2 is F or K \square <223> X at position 5 is C, $\acute{\text{S}}$ or D \square <223> X at position 9 is D or C □<223> X at position 11 is C, S or D □<223> X at position 14 is a hydrogen or a peptidyl chain of 1 (to 12 amino acids) same en **□≪400)>** 45 (Xaa) Xaa Leu Phe Xaa Asn Val Asn Xaa Val Xaa Asn Phe Xaa



PATENT APPLICATION: US/10/032,221

DATE: 01/15/2002 TIME: 15:30:44

Input Set : A:\14401027016.txt

Output Set: N:\CRF3\01152002\J032221.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application No L:12 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:139 M:252 E: No. of Seq. differs, <211>LENGTH:Input:229 Found:208 SEQ:2 L:266 M:252 E: No. of Seq. differs, <211>LENGTH:Input:227 Found:208 SEQ:6 L:439 M:252 E: No. of Seq. differs, <211>LENGTH:Input:8 Found:0 SEQ:13 L:449 M:252 E: No. of Seq. differs, <211>LENGTH:Input:7 Found:0 SEQ:14 I:917 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:918 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:919 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:955 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:974 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:993 M:259 W: Allowed number of lines exceeded, <223> Other Information: L:1035 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:45 L:1055 M:258 W: Mandatory Feature missing, <221> not found for SEQ ID#:45 ` L:1055 M:258 W: Mandatory Feature missing, <222> not found for SEQ ID#:45 L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45

Welete evert evert